Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

WHO Head Rejects Swine Flu Allegations

By Drug Discovery Trends Editor | June 8, 2010

GENEVA (AP) – The head of the World Health Organization strongly rejected suggestions that her decisions about swine flu were influenced by advisers’ links to pharmaceutical companies.

“At no time, not for one second, did commercial interests enter my decision-making,” WHO Director-General Margaret Chan said.

She also dismissed claims the global health body had stirred unnecessary public fear over the pandemic.

Her statement came in response to an article in the British Medical Journal that questioned the way WHO managed conflicts of interest among its scientific advisers and the transparency of its advice to governments.

WHO’s handling of the outbreak is being reviewed by a 29-member expert panel that will report its findings next year. Critics say many of the panelists are also trusted WHO advisers and government employees who could end up whitewashing any failures.

The names of the scientists who advised Chan on the threat posed by swine flu have never been published and WHO said they will only be released once the pandemic is declared over.

“Our decision not to make these names public was motivated by a desire to protect the experts from commercial or other influences,” Chan said, adding that it was not an attempt to keep the panelists’ deliberations secret.

WHO said it will make records of the advisers’ meetings available to the review panel but hasn’t indicated any willingness to release them publicly.

Chan insisted she was open to the panel’s criticism. “Should this committee decide that the current definition of a pandemic and the phases leading up to its declaration need to be tightened or otherwise revised, this will be another recommendation that we will welcome, and act on.”

Harvey Fineberg, the president of the Institute of Medicine in Washington, said the review panel which he heads will hear from critics of WHO when it next meets from June 30 to July 2.

A report published by the Council of Europe last week said the public health guidelines by WHO, European Union agencies and national governments led to a “waste of large sums of public money and unjustified scares and fears about the health risks faced by the European public.” The report by the EU’s human rights watchdog said decisions about the outbreak were poorly explained and not sufficiently transparent.

Date: June 8, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE